Human CD4+ T-cell Epitope-based Therapeutic For Peanut Allergy
Funder
National Health and Medical Research Council
Funding Amount
$403,121.00
Summary
Peanut allergy affects ~2% of the population and peanuts are the major cause of fatal food-induced anaphylaxis. Peanut allergy usually appears in infancy and persists indefinitely. At present, unlike grass pollen allergy, there is no preventative treatment. Using blood cells from peanut-allergic patients, we will identify the components of major peanut allergens to use in _allergy shots� to develop tolerance on peanut exposure without risking anaphylaxis.
Phase I/IIa Trials Of A Novel T-cell Epitope-based Peptide Therapy For Peanut Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,440,000.00
Summary
Peanut allergy affects ~2% of the population and is the major cause of food triggered deaths from anaphylaxis. Typically peanut allergy is lifelong. Currently there is no specific treatment. Our vast experience in immunology for house dust mite and grass immunotherapy allowed us to identify critical components of peanut proteins needed as a safe vaccine to build tolerance to peanut foods. Now we will progress this novel and revolutionary vaccine through early phase clinical trials.